Timeframe: 2020 – 2023 Goal: Create a comprehensive list of potential drug targets for FLC Principal Investigator: Jesse Boehm, PhD Study overview: This project is part of the Broad Institute’s Rare Cancer Dependency Map Initiative. The project has three main goals to identify potential FLC therapeutics: If fully successful, this effort will nominate high priority …
Timeframe: 2020 – 2023 Goal: Investigate the impact on FLC growth and survival of inhibiting two specific oncogenes identified in previous works Principal Investigator: Praveen Sethupathy, PhD Study overview: Based on previous epigenomic, metabolomic, and microRNA profiling, as well as initial drug studies, the study team has developed two new exciting hypotheses about therapeutic vulnerabilities …
Timeframe: 2020 – 2023 Goals: Assess the potential of the combination of nivolumab, fluorouracil, and interferon alpha-2b as a treatment option for unresectable disease Principal Investigators: Sunyoung Lee, MD and Ahmed Kaseb, MD Study overview: This phase I/II trial studies the side effects and how well the combination of nivolumab, fluorouracil, and interferon alpha-2b work …
Timeframe: 2020 – 2021 Goals: Document mechanisms driving FLC and test if treatment with inhibitors of b-catenin may be a potential therapeutic approach for FLC Principal Investigator: Nikolai Timchenko, PhD Study overview: In the course of studies of pediatric liver cancer, we have identified chromosomal regions (Aggressive Liver Cancer Domains, ALCDs) in multiple liver cancer …
Timeframe: 2020 – 2022 Goal: Model development Principal Investigator: Nabeel Bardeesy, PhD Study overview: While multiple FLC models have recently been developed, additional model development remains a priority for the FLC community. This effort aimed to develop multiple different FLC models as resources for the FLC research fibrolamellar cancer research community, collaborating with the Fibrolamellar …
Timeframe: 2020 – 2021 Goal: Understand the characteristics of the immune cells within FLC, and use this knowledge to optimize immunotherapy for this diseasePrincipal Investigator: Venu Pillarisetty, MD Study overview: Despite the application of many advanced treatments, such as surgery and chemotherapy, most patients with FL-HCC die of the disease. The immune system serves to …